betrixaban (Bevyxxa)
Jump to navigation
Jump to search
Indications
- prevention of venous thromboembolism in hospitalized medical patients (FDA-approved June 2017)
Dosage
Pharmacokinetics
Adverse effects
-increased risk of hemorrhage
Mechanism of action
More general terms
References
- ↑ Green D Prevention of Venous Thromboembolism in Hospitalized Medical Patients. NEJM Journal Watch. June 2, 2016 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Cohen AT, Harrington RA, Goldhaber SZ et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016 May 27 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27232649 - ↑ Gibson CM, Chi G, Halaby R et al Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 Feb 14;135(7):648-655. Epub 2016 Nov 14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27881569
- ↑ Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ 4.0 4.1 Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION BEVYXXA <TM> (betrixaban) capsules, for oral use. https://www.bevyxxa.com/wp-content/uploads/2017/11/bevyxxa-betrixaban-capsules-prescribing-information-pdf.pdf